BioDlink Successfully Ships Bevacizumab to Colombia, Paving Way for Cancer Treatment Access

BioDlink Marks Milestone with Bevacizumab Shipment to Colombia

BioDlink Biopharm Co., Ltd. announced a significant achievement with the successful international shipment of its Bevacizumab injection biosimilar to Colombia, in collaboration with Kexing BioPharm. This momentous occasion comes approximately two months after receiving marketing approval from Colombia’s National Institute for Surveillance of Medicines and Foods (INVIMA). The shipment represents not just a commercial victory, but also an important step toward improving access to targeted cancer therapies in the Latin American market.

Bevacizumab is a targeted monoclonal antibody that plays a crucial role in treating various forms of cancer, primarily metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC), both of which are significant contributors to cancer-related mortality in Colombia. As reported by the GLOBOCAN 2022 dataset, the country faced 117,620 new cancer cases in 2022, with colorectal and lung cancers representing combined incidents of over 18,000 cases.

At a celebratory event held to mark the shipment, BioDlink's representatives highlighted the importance of this milestone not only for the company but also for the broader healthcare landscape in Colombia. The two companies utilized specially decorated transportation vehicles, symbolizing their commitment to delivering high-quality cancer therapies to patients who need them most.

The strategic launch follows a rigorous approval process, signaling BioDlink's operational efficiency and its robust platform for commercializing biosimilars. Over the past four years, BioDlink's manufacturing facilities, measuring 50,000 square meters, have consistently passed EU Qualified Person audits, underscoring their commitment to maintaining high production standards with zero critical defects.

In addition to its Philippine framing, BioDlink has also secured Good Manufacturing Practice (GMP) certifications in several key countries including Brazil, Colombia, Argentina, and others across South America and Asia. This positions BioDlink uniquely within emerging markets, showcasing its capacity for localized manufacturing while enhancing patient access to effective treatments.

As BioDlink established a partnership with Kexing BioPharm in early 2022, the two organizations have optimally integrated their research and development, manufacturing capabilities, and market access strategies into a unique closed-loop model. Kexing, recognized as a global licensee of Bevacizumab in emerging markets, is leading regulatory filings in approximately 35 countries, further expanding the reach of this vital therapeutic.

This collaboration is seen as a keystone in BioDlink's strategy to penetrate other significant markets, including South Asia, Southeast Asia, and Africa. As the companies work to bring more biomedical innovations to patients around the world, they uphold a shared commitment to the philosophy of “Quality First, Innovation Driven, Success Together.”

The successful shipment of Bevacizumab to Colombia not only reflects BioDlink's dedication to improving global health access but also symbolizes a hope for many patients battling these life-threatening cancers. By continuing to streamline production and regulatory processes, BioDlink aims to further enhance its presence in the biopharmaceutical arena and ultimately contribute to a healthier global community.

With rising cancer incidences globally, the need for effective treatments like Bevacizumab remains critical. This inaugural shipment to Colombia is a hopeful sign that BioDlink and Kexing BioPharm are poised to play a significant role in the fight against cancer, providing necessary support to patients in desperate need of innovative therapies.

In 2023, global sales for Bevacizumab reached approximately USD 8.5 billion, underscoring its importance and effectiveness in cancer treatment. As BioDlink continues to bolster its operational efficiencies and expand its international footprint, the future looks promising for both the company and patients alike.

For further information about BioDlink and its products, visit their official website.